Surveillance, Epidemiology, and End Results Program. Cancer stat facts: ovarian cancer. Accessed July 21, 2022. Available at: https://seer.cancer.gov/statfacts/html/ovary.html
Terplan M, Schluterman N, McNamara EJ, et al. Have racial disparities in ovarian cancer increased over time? An analysis of SEER data. Gynecol Oncol 2012;125:19–24.
Barnholtz-Sloan JS, Tainsky MA, Abrams J, et al. Ethnic differences in survival among women with ovarian carcinoma. Cancer 2002;94:1886–1893.
Bristow RE, Chang J, Ziogas A, et al. Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status. Gynecol Oncol 2014;134:60–67.
Bristow RE, Powell MA, Al-Hammadi N, et al. Disparities in ovarian cancer care quality and survival according to race and socioeconomic status. J Natl Cancer Inst 2013;105:823–832.
Harlan LC, Clegg LX, Trimble EL. Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol 2003;21:3488–3494.
Parham G, Phillips JL, Hicks ML, et al. The National Cancer Data Base report on malignant epithelial ovarian carcinoma in African-American women. Cancer 1997;80:816–826.
Armstrong DK, Alvarez RD, Backes FJ, et al. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer. Version 3.2022. Accessed July 21, 2022. To view the most recent version, visit https://www.nccn.org
Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248–1259.
Farley JH, Tian C, Rose GS, et al. Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials. Cancer 2009;115:4210–4217.
Winter WE III, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2007;25:3621–3627.
Penchansky R, Thomas JW. The concept of access: definition and relationship to consumer satisfaction. Med Care 1981;19:127–140.
Karanth S, Fowler ME, Mao X, et al. Race, socioeconomic status, and health-care access disparities in ovarian cancer treatment and mortality: systematic review and meta-analysis. JNCI Cancer Spectr 2019;3:pkz084.
Long B, Chang J, Ziogas A, et al. Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California. Am J Obstet Gynecol 2015;212:468.e1–468.e9.
Hodeib M, Chang J, Liu F, et al. Socioeconomic status as a predictor of adherence to treatment guidelines for early-stage ovarian cancer. Gynecol Oncol 2015;138:121–127.
Goldberg EM, Berger Y, Sood D, et al. Differences in sociodemographic disparities between patients undergoing surgery for advanced colorectal or ovarian cancer. Ann Surg Oncol 2021;28:7795–7806.
Klabunde CN, Warren JL, Legler JM. Assessing comorbidity using claims data: an overview. Med Care 2002;40(Suppl):IV-26–35.
Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130–1139.
Morgan RJ Jr, Alvarez RD, Armstrong DK, et al. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer. Version 2.2013. J Natl Compr Canc Netw 2013;11:1199–1209.
Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159:702–706.
Howell EA, Egorova N, Hayes MP, et al. Racial disparities in the treatment of advanced epithelial ovarian cancer. Obstet Gynecol 2013;122:1025–1032.
Taylor JS, He W, Harrison R, et al. Disparities in treatment and survival among elderly ovarian cancer patients. Gynecol Oncol 2018;151:269–274.
Bandera EV, Lee VS, Rodriguez-Rodriguez L, et al. Racial/ethnic disparities in ovarian cancer treatment and survival. Clin Cancer Res 2016;22:5909–5914.
Terplan M, Smith EJ, Temkin SM. Race in ovarian cancer treatment and survival: a systematic review with meta-analysis. Cancer Causes Control 2009;20:1139–1150.
Long B, Chang J, Ziogas A, et al. Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California. Am J Obstet Gynecol 2015;212:468.E1–468.E9.
Bristow RE, Chang J, Ziogas A, et al. Sociodemographic disparities in advanced ovarian cancer survival and adherence to treatment guidelines. Obstet Gynecol 2015;125:833–842.
Bristow RE, Zahurak ML, Ibeanu OA. Racial disparities in ovarian cancer surgical care: a population-based analysis. Gynecol Oncol 2011;121:364–368.
Bristow RE, Chang J, Ziogas A, et al. Adherence to treatment guidelines for ovarian cancer as a measure of quality care. Obstet Gynecol 2013;121:1226–1234.
Austin S, Martin MY, Kim Y, et al. Disparities in use of gynecologic oncologists for women with ovarian cancer in the United States. Health Serv Res 2013;48:1135–1153.
Bristow RE, Chang J, Ziogas A, et al. High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease. Gynecol Oncol 2014;132:403–410.
Cronin KA, Howlader N, Stevens JL, et al. Racial disparities in the receipt of guideline care and cancer deaths for women with ovarian cancer. Cancer Epidemiol Biomarkers Prev 2019;28:539–545.
Ulmer KK, Greteman B, Cardillo N, et al. Disparity of ovarian cancer survival between urban and rural settings. Int J Gynecol Cancer 2022;32:540–546.
Casagrande SS, Gary TL, LaVeist TA, et al. Perceived discrimination and adherence to medical care in a racially integrated community. J Gen Intern Med 2007;22:389–395.
Jacobs EA, Rathouz PJ, Karavolos K, et al. Perceived discrimination is associated with reduced breast and cervical cancer screening: the Study of Women’s Health Across the Nation (SWAN). J Womens Health (Larchmt) 2014;23:138–145.
- Search Google Scholar
- Export Citation
, Jacobs EA , Rathouz PJ , Karavolos K Perceived discrimination is associated with reduced breast and cervical cancer screening: the Study of Women’s Health Across the Nation (SWAN). J Womens Health (Larchmt) 2014; 23: 138– 145. 10.1089/jwh.2013.4328
Mullins MA, Peres LC, Alberg AJ, et al. Perceived discrimination, trust in physicians, and prolonged symptom duration before ovarian cancer diagnosis in the African American Cancer Epidemiology Study. Cancer 2019;125:4442–4451.
- Search Google Scholar
- Export Citation
, Mullins MA , Peres LC , Alberg AJ Perceived discrimination, trust in physicians, and prolonged symptom duration before ovarian cancer diagnosis in the African American Cancer Epidemiology Study. Cancer 2019; 125: 4442– 4451. 31415710 10.1002/cncr.32451
Starbuck KD, Szender JB, Duncan WD, et al. Prognostic impact of adjuvant chemotherapy treatment intensity for ovarian cancer. PLoS One 2018;13:e0206913.
Wright J, Doan T, McBride R, et al. Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival. Br J Cancer 2008;98:1197–1203.
Denduluri N, Lyman GH, Wang Y, et al. Chemotherapy dose intensity and overall survival among patients with advanced breast or ovarian cancer. Clin Breast Cancer 2018;18:380–386.